secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010774
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M
-----------------------------------------------------------------------

- Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.
- First US patient dosing for SIM0505 expected in Q3 2025; Phase 1 data in China showed partial response.
- LNCB74 (B7-H4 ADC) Phase 1 in cohort 4; backfill cohorts planned H2 2025.
- Cash $35.3M as of June 30, 2025; expects to fund operations into mid-2026.
- Simcere Zaiming made $2M equity investment; regained Nasdaq minimum bid price compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/0001558370-25-010774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer